Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...
The Food and Drug Administration has announced some major changes to the review process for drug developers in the United States. It could cut down the time from 10 to 12 months for a review to just ...
Food and Drug Administration commissioner Marty Makary's flagship effort to overhaul how the agency reviews drugs is facing ...
FDA officials told GAO that competing priorities and an agency reorganization in late 2024 have slowed progress, estimating ...
The Food and Drug Administration (FDA) development and approval process for drugs and medical devices involves multiple phases that ensure the safety and effectiveness of products before and after ...
A Government Accountability Office (GAO) report released yesterday finds that while the US Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results